Header Logo

Connection

Alan Landay to Cyclohexanes

This is a "connection" page, showing publications Alan Landay has written about Cyclohexanes.
Connection Strength

0.670
  1. Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. J Infect Dis. 2017 10 17; 216(7):813-818.
    View in: PubMed
    Score: 0.152
  2. Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS. 2016 08 24; 30(13):2091-7.
    View in: PubMed
    Score: 0.140
  3. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clin Infect Dis. 2015 Oct 01; 61(7):1179-88.
    View in: PubMed
    Score: 0.129
  4. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013 Jun 06; 121(23):4635-46.
    View in: PubMed
    Score: 0.111
  5. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15; 206(4):534-42.
    View in: PubMed
    Score: 0.105
  6. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Na?ve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog. 2016 Jan; 12(1):e1005381.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.